The International Society for Cell & Gene Therapy (ISCT), a global society of over 3,000 members dedicated to translating cell and gene therapies (CGT) into safe and effective treatments to improve patients’ lives, recently hosted its largest event ever. focused on translation connects academia, regulatory, and industry experts from around the world to collaborate and find real solutions to the most critical issues influencing the development of advanced therapeutics.
The event took place in Paris, France.
The ISCT Translation Pathway Program 2023 features plenary and concurrent sessions designed to address and address barriers at each stage of development across multiple modalities such as CAR T, iPSC, and dedicated half-day programs to unlock potential exosomes (EVs).
In this week’s podcast, we look into two sessions: ‘Will allogeneic cell therapy replace autologous when it comes to patient access?’ and ‘Do exosomes replace MSCs?’
Our guests to talk on this topic are Carole Nicco, CSO at BioSenic; Dalip Sethi, director of scientific affairs, Terumo Blood and Cell Technologies; Matthieu de Kalbermatten, CEO of CellProthera; and Vered Caplan, CEO of Orgenesis.